19:10 , Feb 22, 2019 |  BC Week In Review  |  Financial News

Peloton planning Phase III kidney cancer study with $150M series E

With the proceeds of its new $150 million series E round, Peloton Therapeutics Inc. (Dallas, Texas) plans to start a Phase III trial next half of lead candidate PT2977 to treat advanced renal cell carcinoma...
19:51 , Feb 20, 2019 |  BC Extra  |  Financial News

Peloton planning Phase III kidney cancer study with $150M series E

With the proceeds of its new $150 million series E round, Peloton Therapeutics Inc. (Dallas, Texas) plans to start a Phase III trial next half of lead candidate PT2977 to treat advanced renal cell carcinoma...
18:39 , Sep 7, 2018 |  BC Week In Review  |  Financial News

4D Molecular rises $90M series B

Gene therapy company 4D Molecular Therapeutics Inc. (Emeryville, Calif.) raised $90 million on Sept. 5 in an untranched series B round led by new investor Viking Global Investors. Fellow new investors ArrowMark Partners, Janus Henderson...
12:01 , Sep 5, 2018 |  BC Extra  |  Financial News

4D Molecular raises $90M series B

Gene therapy company 4D Molecular Therapeutics Inc. (Emeryville, Calif.) raised $90 million in an untranched series B round led by new investor Viking Global Investors. Fellow new investors ArrowMark Partners, Janus Henderson Investors, The Biotechnology...
02:28 , May 18, 2018 |  BC Week In Review  |  Financial News

MEI Pharma raises $75M in private placement

MEI Pharma Inc. (NASDAQ:MEIP) raised $75 million on May 14 through the sale of 33 million units at $2.27 in a private placement led by Vivo Capital and CAM Capital. Also participating were New Enterprise...
17:52 , May 14, 2018 |  BC Extra  |  Financial News

MEI Pharma raises $75M in private placement

MEI Pharma Inc. (NASDAQ:MEIP) added $0.30 (13%) to $2.53 on Monday after it raised $75 million through the sale of 33 million units at $2.27 in a private placement led by Vivo Capital and CAM...
18:11 , Mar 9, 2018 |  BC Week In Review  |  Financial News

Viewpoint raises $35M series B

ViewPoint Therapeutics Inc. (San Francisco, Calif.) raised $35 million on March 5 in a series B round led by The Rise Fund, a fund managed by TPG Growth. New investor Novo Holdings A/S (Hellerup, Denmark)...
18:43 , Mar 5, 2018 |  BC Extra  |  Financial News

Ophthalmic play ViewPoint raises $35M series B

ViewPoint Therapeutics Inc. (San Francisco, Calif.) raised $35 million in a series B round led by The Rise Fund, a fund managed by TPG Growth. New investor Novo Holdings A/S (Hellerup, Denmark) also participated, as...
00:29 , Oct 20, 2017 |  BC Week In Review  |  Company News

Syndax licenses menin-MLL inhibitors from Allergan

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) obtained an exclusive, worldwide license to inhibitors of the menin-MLL fusion oncogene from the Vitae Pharmaceuticals Inc. subsidiary of Allergan plc (NYSE:AGN). Syndax plans to begin clinical trials in 2019 of...
20:21 , Oct 17, 2017 |  BC Extra  |  Company News

Syndax in menin-MLL deal with Allergan

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) obtained an exclusive, worldwide license to inhibitors of the menin-MLL fusion oncogene from the Vitae Pharmaceuticals Inc. subsidiary of Allergan plc (NYSE:AGN). Syndax plans to begin clinical trials in 2019 of...